

Documented results. Supported by science.

Vasomedical Inc. provides superior medical products and services that address unmet clinical needs in the management of patients with heart disease.

The company's core technology, EECP® therapy, provides healthcare professionals with a noninvasive therapy for patients suffering from cardiovascular diseases. EECP® therapy helps patients and their families lead active and productive lives.

NASDAQ SmallCap™	VASO
Recent Close (1/19/06)	\$0.24
52-week Trading Range	\$0.16– \$1.98
Market Cap. (1/19/06)	\$14.99 million
Shares Outstanding	62.46 million
Loss per Share (MRQ)	(\$0.18)
Fiscal Year End	May 31

EECP® THERAPY: NONINVASIVE THERAPY FOR CARDIOVASCULAR DISEASE

The EECP® system is a microprocessor-based device that delivers a pressure wave to the heart, increasing blood flow and reducing the heart's workload. EECP® therapy increases circulation in areas of the heart with less than adequate blood supply and improves systemic vascular function.

EECP® THERAPY: BENEFITS FOR ALL STAKEHOLDERS

Stakeholder	EECP® THERAPY ADVANTAGE
Physicians	Ability to administer a more comprehensive treatment regimen Incremental source of revenue
Patients	Noninvasive treatment alternative Clinically proven to improve outcomes
Payers	A more cost effective alternate to costly, high-risk invasive procedures

CMS established a national Medicare reimbursement policy for EECP® therapy in the treatment of patients with angina and angina-like symptoms in 1999.

Extensive third-party coverage policies have been established on an individual provider basis; currently, over 300 third-party payers cover EECP® treatment.

INVESTMENT CONSIDERATIONS

- EECP® systems are cleared to market for treating the following four cardiovascular conditions: angina, congestive heart failure, cardiogenic shock and acute myocardial infarction. Currently marketed for angina and heart failure.
- Approximately 66% of EECP® patients are covered by Medicare.
- Approximately 80% market share, with over 800 EECP® systems installed worldwide.
- Significant opportunity to grow the market for EECP® therapy and further increase sales.
- Management and sales team focused on delivering tangible results. Targeted growth strategy with long-term goal of achieving broad-based clinical acceptance of EECP® therapy; extensive marketing initiatives underway.

MANAGEMENT TEAM

Thomas Glover

President and Chief Executive Officer, Director

Thomas W. Fry

Chief Financial Officer

John C. K. Hui, Ph.D.

Senior VP, Chief Technology Officer, Director

Harold Kaefer

VP, Engineering and Manufacturing

Larry Liebman

VP, Sales

Thomas R. Varricchione

VP, Clinical and Regulatory Affairs

Brian M. Weber

VP, Marketing

BOARD OF DIRECTORS

Abraham E. Cohen

Chairman

Alexander G. Bearn, M.D.

David S. Blumenthal, M.D.

Thomas Glover

John C. K. Hui, Ph.D.

Photios T. Paulson

Kenneth W. Rind, Ph.D.

Martin Zeiger

GROWTH STRATEGY

- Market EECP® therapy for CHF under existing national angina Medicare policy
- Obtain national Medicare and third-party payer coverage for CHF beyond patients covered under current policies
- Increase penetration of core U.S. angina market
- Pursue additional managed care relationshipsExpand revenue streams from service, education & consumables

CORPORATE HEADQUARTERS

Vasomedical, Inc.

180 Linden Avenue

Westbury, NY 11590

Phone: (516) 997-4600

Fax: (516) 997-2299

www.vasomedical.com

www.eecp.com

www.naturalbypass.com

INVESTOR RELATIONS

Email: investorrelations@vasomedical.com

Vasomedical Inc.  **EECP®**

Documented results. Supported by science.

This corporate profile may include predictions, estimates and other information that might be considered forward-looking. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ from those anticipated as a result of various factors, including the effect of business and economic conditions; medical insurance reimbursement policies; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and other risks identified in Vasomedical's filings with the U.S. Securities and Exchange Commission.

V15-0073 Rev.2